- Home
- INO vs NRXP Comparison
INO vs NRXP Comparison
Compare INO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- NRXP
- Stock Information
- Founded
- INO 1979
- NRXP 2015
- Country
- INO United States
- NRXP United States
- Employees
- INO N/A
- NRXP N/A
- Industry
- INO Medical/Dental Instruments
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- INO Health Care
- NRXP Health Care
- Exchange
- INO Nasdaq
- NRXP Nasdaq
- Market Cap
- INO 69.3M
- NRXP 58.5M
- IPO Year
- INO 1998
- NRXP N/A
- Fundamental
- Price
- INO $2.18
- NRXP $2.92
- Analyst Decision
- INO Buy
- NRXP Strong Buy
- Analyst Count
- INO 5
- NRXP 5
- Target Price
- INO $8.80
- NRXP $31.40
- AVG Volume (30 Days)
- INO 2.1M
- NRXP 498.6K
- Earning Date
- INO 11-13-2025
- NRXP 11-13-2025
- Dividend Yield
- INO N/A
- NRXP N/A
- EPS Growth
- INO N/A
- NRXP N/A
- EPS
- INO N/A
- NRXP N/A
- Revenue
- INO $182,337.00
- NRXP N/A
- Revenue This Year
- INO N/A
- NRXP N/A
- Revenue Next Year
- INO $15,960.33
- NRXP $231.16
- P/E Ratio
- INO N/A
- NRXP N/A
- Revenue Growth
- INO N/A
- NRXP N/A
- 52 Week Low
- INO $1.30
- NRXP $1.10
- 52 Week High
- INO $7.00
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- INO 47.09
- NRXP 54.61
- Support Level
- INO $2.33
- NRXP $2.73
- Resistance Level
- INO $2.98
- NRXP $3.18
- Average True Range (ATR)
- INO 0.20
- NRXP 0.24
- MACD
- INO -0.07
- NRXP 0.04
- Stochastic Oscillator
- INO 2.44
- NRXP 71.04
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.